The transcription factor and oncoprotein MYC is a potent driver of many human cancers and
can regulate numerous biological activities that contribute to tumorigenesis. How a single …

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Myc is an oncogene deregulated in most—perhaps all—human cancers. Each Myc family
member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance …

Colorectal cancer (CRC) represents the third most commonly diagnosed cancer and the
second leading cause of cancer death worldwide. The modern concept of cancer biology …

The MYC proto-oncogene is a gene product that coordinates the transcriptional regulation of
a multitude of genes that are essential to cellular programs required for normal as well as …

First designed and published in 1998 as a laboratory tool to study Myc perturbation,
Omomyc has come a long way in the past 22 years. This dominant negative has contributed …

Extensive research efforts have been made and are still ongoing in the search for an ideal
anti-cancer therapy. Almost all chemotherapeutics require a carrier or vehicle, a drug …

The transcription factor MYC is overexpressed in most cancers, where it drives multiple
hallmarks of cancer progression. MYC is known to promote oncogenic transcription by …

Simple Summary Presently, the study of cancer stem cells is important because these cells
increase the cancer complexity, confer tumors the ability to grow, resist treatment, and …

Cancer stem cells (CSCs) contribute to tumor initiation, progression, and recurrence in many
types of cancer, including hepatocellular carcinoma (HCC). Epigenetic reprogramming of …